Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.57 |
| ▸ | RAF1 | P04049 | 3/20 | 0.56 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | BRAF | P15056 | 5/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16735356 | 0.78 | RAF1 (0.84) | RIPK1RAF1KDRBRAFTRPV1 | |
| SCHEMBL13553004 | 0.77 | KDR (0.58) | RIPK1KDRBRAFTRPV1 | |
| SCHEMBL13459579 | 0.75 | RIPK1 (0.79) | RIPK1RAF1KDRTRPV1CA9 | |
| SCHEMBL16735355 | 0.75 | RAF1 (0.66) | RIPK1RAF1KDRBRAFTRPV1 | |
| SCHEMBL3235295 | 0.74 | KDR (0.64) | RIPK1KDRBRAFTRPV1MAPK14 | |
| SCHEMBL16735269 | 0.72 | RAF1 (1.00) | RIPK1RAF1KDRBRAF | |
| SCHEMBL4548243 | 0.72 | KDR (0.80) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL14146746 | 0.71 | KDR (0.74) | KDRTRPV1CA9CA1CA2 | |
| SCHEMBL30503358 | 0.71 | KDR (0.65) | RIPK1RAF1KDRBRAFTRPV1 | |
| SCHEMBL13556584 | 0.70 | KDR (0.82) | KDRTRPV1CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388165-B2 | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2016-07-12 | — | — | US | disclosed |
| US-20150191450-A1 | ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191450-A1 | ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CSNK1A1, MAP3K5, MAP4K2 | RIPK1 396/4885RAF1 96/4885KDR 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.